GlaxoSmithKline PLC agreed to buy out Novartis AG’s stake in their consumer-health joint venture for US$13 billion, days after abandoning its pursuit of a similar unit put on the block by Pfizer Inc.
The transaction gives Glaxo full control of a business that sells Theraflu cold medicine and Panadol pain relievers while arming Novartis with more firepower for its pharmaceutical operations and acquisitions. It is the first big strategic move for new chief executive officers at two of Europe’s largest drug companies.
Glaxo chief executive officers Emma Walmsley, who took over last year, has emphasized the benefit of having the pharmaceutical, vaccine and consumer businesses under one umbrella, partly due to the drug industry’s volatility.
Her counterpart at Novartis, Vas Narasimhan, who rose to the top spot last month, said the over-the-counter business is no longer central to the Swiss company’s strategy.
Glaxo shares rose as much as 2.8 percent early yesterday in London, while Novartis rose as much as 2 percent in Zurich, Germany.
The consumer health sector has experienced pressure on prices as drugstores and other retailers vie to get shoppers.
Glaxo’s investors balked last year when Walmsley mentioned interest in the Pfizer unit, fearing that it might endanger the British drugmaker’s dividend.
Novartis had the right, starting this month, to require Glaxo to purchase its stake in the venture. The new agreement removes uncertainty surrounding that option, Glaxo said yesterday.
The consumer business expects operating margins to improve and approach “mid-20s” percentages by 2022, Glaxo said.
The sale of the 36.5 percent stake in the venture, which was formed in 2015, should close in the second quarter, Basel, Switzerland-based Novartis said yesterday in a statement.
The sale would also strengthen Novartis’s ability to drive shareholder returns and make bolt-on acquisitions, Narasimhan said in the statement.
“While our consumer healthcare joint venture with GSK is progressing well, the time is right for Novartis to divest a noncore asset at an attractive price,” Narasimhan said.
Narasimhan is focusing on finding breakthrough drugs for cancer and other diseases. Novartis reiterated in January that a decision on whether to spin-off the Alcon eye-care division probably would not come before the first half of next year.
Glaxo is starting a review of its Horlicks unit and other consumer-health nutrition products to help fund the transaction and increase focus on the over-the-counter and oral-health categories. The company expects to conclude that process around the end of this year.
Glaxo pulled out of the contest for Pfizer’s consumer-health unit last week in a development that leaves the US drugmaker with dwindling options to dispose of the business, which is valued at as much as US$20 billion.
One factor in Glaxo’s decision not to pay the price Pfizer wanted was a potential transaction to buy out the Novartis holding, analysts at Bloomberg Intelligence wrote last week.
Glaxo had said it would be interested in acquiring the stake if Novartis exercised its option to sell.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy